Category: Tysabri

PML, a Rare Side Effect of Tysabri, Found to Worsen Long-Term Disability in Patients with MS

 October 11, 2023 Rosanna Sutherby, Pharm.D. Progressive multifocal leukoencephalopathy (PML) is caused by John Cunningham virus (JCV). A recently published…

Stuart Schlossman

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial

 Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; et al Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6 Author Affiliations Article Information JAMA Neurol. Published online January 23, 2023. doi:10.1001/jamaneurol.2022.5007 Key Points Question  Does proposed biosimilar…

Stuart Schlossman

JC Virus Mutations May Predict Rare Brain Infection Linked to Tysabri

 By Steve Bryson PhD on Oct 04, 2021  Mutations in the John Cunningham virus may serve as an early predictor…

Stuart Schlossman

6-Week Dosing of Natalizumab Effective, May Reduce PML Risk

August 3, 2021 –   Abby Reinhard  Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…

Stuart Schlossman

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

  Enrique Alvarez 1, Kavita V Nair 2, Brian D Hoyt 3, Rebecca A Seale 1, Stefan Sillau 1, Augusto Miravalle 4, Eric Engebretson 1, Brittany Schurr 1, John R Corboy 1, Timothy L Vollmer 1, Justin M Honce 5 Affiliations …

Stuart Schlossman

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

 AUGUST 2, 2021 •                     Results show that every six-week natalizumab IV administration…

Stuart Schlossman

At-home Tysabri Infusions Appear as Safe, Effective as Those at Clinics

 by Forest Ray PhD | July 26, 2021 Tysabri (natalizumab) infusions given in the home to people with relapsing-remitting multiple sclerosis (RRMS) save money and are…

Stuart Schlossman

Biogen Issued CRL (complete response letter) for Subcutaneous Natalizumab in Relapsing MS

 Just weeks after receiving an EU marketing authorization, the FDA has issued a complete response letter to Biogen for its…

Stuart Schlossman

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis

 Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian…

Stuart Schlossman

Natalizumab Improves Social and Mental Health in Patients with Multiple Sclerosis

 April 24, 2021  – Victoria Johnson Conferences | American Academy of Neurology Annual Meeting Researchers compared Neuro-QoL scores between patients treated with…

Stuart Schlossman

Categories

Latest Blog Posts